Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Accumulated Expenses (2016 - 2024)

Lifecore Biomedical, Inc. \De\ (LFCR) has 14 years of Other Accumulated Expenses data on record, last reported at $9.9 million in Q4 2024.

  • For Q4 2024, Other Accumulated Expenses rose 28.85% year-over-year to $9.9 million; the TTM value through Nov 2024 reached $9.9 million, up 28.85%, while the annual FY2024 figure was $9.4 million, 30.97% up from the prior year.
  • Other Accumulated Expenses reached $9.9 million in Q4 2024 per LFCR's latest filing, down from $11.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $13.7 million in Q1 2022 and bottomed at $3.7 million in Q3 2020.
  • Average Other Accumulated Expenses over 5 years is $8.6 million, with a median of $9.1 million recorded in 2024.
  • Peak YoY movement for Other Accumulated Expenses: soared 460.6% in 2020, then tumbled 69.48% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $12.7 million in 2020, then plummeted by 69.48% to $3.9 million in 2021, then skyrocketed by 168.71% to $10.4 million in 2022, then fell by 26.56% to $7.7 million in 2023, then increased by 28.85% to $9.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $9.9 million in Q4 2024, $11.4 million in Q3 2024, and $9.4 million in Q2 2024.